Granzyme K Protein Linked to Age-Related Organ Damage
Monash University researchers found that blocking the immune-cell protein improved heart function and reduced damage in older mice.
Updated on Nov. 13, 2026 in Diseases — General

Monash University researchers identified the protein Granzyme K as a driver of age-related damage to the heart, liver and kidneys. The findings, published in Immunity, come from preclinical mouse studies that compared older mice with and without the protein.
Why it matters
Ageing is one of the biggest risk factors for chronic conditions, including cardiovascular and kidney disease, so a protein that contributes to organ damage could be a target for future treatments. The work points to a possible way to address these conditions at a biological level rather than only managing their symptoms.
The evidence comes from a preclinical mouse model study, with elevated Granzyme K levels also found in human patients with lupus nephritis and heart failure. Whether the same benefits seen in mice would apply to people has not yet been determined.
The players
Monash University
Monash University is a large public research university in Melbourne, Australia, known for its work across medicine, science and engineering.
The details
Researchers compared older mice without Granzyme K against those with it, finding that the mice lacking the protein showed improved heart function, less fibrosis, and fewer signs of age-related damage in the liver and kidneys. Mice without Granzyme K also showed normal immune system aging.
Timeline
The study was published in the journal Immunity.
A news report on the findings was published on news-medical.net on 12 November 2026.
Health Landscape
Ageing is widely recognised as a leading risk factor for chronic cardiovascular and kidney disease, and this study extends that understanding by identifying Granzyme K as a specific immune-cell protein that contributes to organ damage in older mice. The finding adds to a growing body of research aimed at targeting the biology of ageing rather than treating its diseases one at a time.
For now, the findings do not change how people with heart, kidney or liver conditions are treated, since the work so far is limited to mice and early human data. Researchers are still investigating whether blocking Granzyme K could one day provide protection in people.
The takeaway
Ageing drives much of the risk for chronic heart and kidney disease, and identifying specific proteins behind that damage opens the door to more targeted approaches. Readers should watch for follow-up research testing whether these findings hold in humans.
Further reading
For more on how ageing relates to chronic illness, explore our Diseases — General coverage.







